Johnson & Johnson Acquires Atraverse Medical

Johnson & Johnson to Acquire Atraverse Medical

April 26, 2026

Medical Devices

Johnson & Johnson entered into a definitive agreement to acquire Atraverse Medical, a privately held medtech company developing the HOTWIRE Transseptal Access System for left-heart access during cardiac electrophysiology procedures. The deal is expected to close in Q2 2026, subject to customary closing conditions, with financial terms not disclosed.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.

Johnson & Johnson to Acquire V-Wave for Up to $1.7 Billion

October 9, 2024

Healthcare Services

Johnson & Johnson (J&J) entered into a definitive agreement to acquire V-Wave, a privately held heart-failure treatment company, for an upfront payment of $600 million and potential regulatory/commercial milestone payments up to about $1.1 billion (total up to ~$1.7 billion). The acquisition is expected to close before the end of 2024, and will add V-Wave’s Ventura Interatrial Shunt implant technology to the J&J MedTech Cardiovascular portfolio.

Johnson & Johnson MedTech Acquires Laminar, Inc.

November 30, 2023

Medical Devices

Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a privately held medical device developer focused on eliminating the left atrial appendage (LAA) in patients with non‑valvular atrial fibrillation, for $400 million upfront plus potential clinical and regulatory milestone payments. Laminar will join Johnson & Johnson MedTech’s Biosense Webster business to expand the company’s electrophysiology and interventional cardiology portfolio and accelerate development and commercialization of Laminar’s rotational LAA elimination technology.

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Johnson & Johnson (Ethicon) Acquires Auris Health

April 1, 2019

Medical Devices

Johnson & Johnson, through its surgical devices unit Ethicon, completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash with up to $2.35 billion in contingent payments. The deal brings Auris' Monarch robotic bronchoscopy platform and related digital surgery capabilities into J&J's medical devices portfolio to accelerate capability expansion in digital and robotic surgery, particularly for lung cancer diagnosis and intervention.